Abstract:<p>The emergence of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic underscores the importance of the rapid development of a non-invasive vaccine that can be easily administered. A vaccine administered by nasal delivery is endowed with such characteristics against respiratory viruses. In this study, we generated a recombinant SARS-CoV-2 receptor-binding domain (RBD)-based subunit vaccine. Mice were immunized via intranasal inoculation, microneedle-intradermal injection, or intramuscular injection, after which the RBD-specific immune responses were compared. Results showed that when administrated intranasally, the vaccine elicited a robust systemic humoral immunity with high titers of IgG antibodies and neutralizing antibodies as well as a significant mucosal immunity. Besides, antigen-specific T cell responses were also analyzed. These results indicated that the non-invasive intranasal administration should be explored for the future SARS-CoV-2 vaccine design.</p>

What problem does this paper attempt to address?

The main problem this paper attempts to address is the development of a SARS-CoV-2 recombinant receptor-binding domain (RBD) subunit vaccine that can effectively induce a protective immune response through intranasal administration. Specifically, the researchers focus on whether this intranasal vaccine can more effectively induce systemic and mucosal immune responses compared to traditional injection methods (such as intradermal or intramuscular injection), including the production of high levels of neutralizing antibodies, a balanced Th1/Th2 cell immune response, and significant mucosal immune responses. Additionally, the study explores the role of aluminum adjuvants in enhancing the efficacy of the intranasal vaccine. The importance of this study lies in its exploration of a non-invasive vaccine delivery method, which not only improves the convenience of vaccination and reduces the demand for medical resources but also potentially provides better protective effects, especially in the prevention of respiratory viruses. This has significant practical implications for the current COVID-19 pandemic.

Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse